• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Entos Pharmaceuticals announces research, development and collaboration agreement

Bioengineer by Bioengineer
October 2, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: (c) Entos Pharmaceuticals

EDMONTON, Alberta, October 2, 2019 — Entos Pharmaceuticals Inc. (“Entos” or the “Company”), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement (“Agreement”) with a clinical stage biopharmaceutical company (“Partner”) focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

Under the terms of the agreement, the Partner has the option to exclusively license candidates developed under the Agreement from Entos for further development and commercialization. In return, Entos receives research funding and is eligible for option exercise fees, research, development, regulatory, and sales milestone payments of up to US$109 million. In addition, the Partner will pay Entos undisclosed royalties on sales of products resulting from the collaboration.

“This marks our second major collaboration for the Fusogenix technology and represents further validation of our non-viral repeat dosing nucleic acid delivery platform,” said Dr. John Lewis, President & CEO of Entos. “We are excited to be working with our new partner to develop new clinical immunotherapy candidates.”

Deloitte Corporate Finance Inc. acted as exclusive financial advisor and Norton Rose Fulbright Canada LLP acted as legal counsel to Entos on the transaction.

###

About Entos Pharmaceuticals, Inc.

Entos is focused on the development of next-generation nucleic acid-based therapies using its proprietary Fusogenix drug delivery system. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, and CRISPR. For more information, visit http://www.entospharma.com

For more information regarding this press release, contact:

Entos Contact

John D. Lewis, Ph.D.

President & CEO, Entos Pharmaceuticals, Inc.

Phone: (780) 862-7445

Email: [email protected]

Media Contact
John D. Lewis
[email protected]

Tags: Biomedical/Environmental/Chemical EngineeringBiotechnologyCollaborationImmunology/Allergies/AsthmaMedicine/HealthNanotechnology/MicromachinesPharmaceutical SciencePharmaceutical SciencesResearch/Development
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Solving Forensic Mysteries: Genealogy’s Emerging Solutions

August 5, 2025
blank

Maternal Inflammation in Second Trimester Linked to Birth Risks

August 5, 2025

Why Tension Drives Short-Form Video Addiction

August 5, 2025

Reducing Inflammation to Shield Against Lupus Nephritis

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    70 shares
    Share 28 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Solving Forensic Mysteries: Genealogy’s Emerging Solutions

Optimizing Bacillus cabrialesii HB7 for Saline Stress Relief

PeroCycle Appoints New CEO and Launches £4M Seed Round to Advance Decarbonization in Steelmaking

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.